Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2025-09-24 Sale | 2025-09-26 3:53 pm | Monopar Therapeutics | MNPR | Tactic Pharma LLC Robinson Chandler Brown Michael J O'Halloran Thomas V. Mazar Andrew Paul 10% Owner | 550,229 | $63.61 | $34,999,957 | 272,026 (Direct) | View |
| 2025-04-02 Sale | 2025-04-04 7:27 pm | Monopar Therapeutics | MNPR | Tactic Pharma LLC Robinson Chandler Brown Michael J O'Halloran Thomas V. Mazar Andrew Paul 10% Owner | 33,334 | $35 | $1,166,690 | 822,255 (Direct) | View |
| 2021-02-11 Sale | 2021-02-16 7:35 pm | Monopar Therapeutics | MNPR | Tactic Pharma LLC Mazar Andrew Paul Robinson Chandler O'Halloran Thomas V. Brown Michael J 10% Owner | 125,000 | $14.64 | $1,830,620 | 4,277,940 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2025-04-01 Option Award | 2025-04-02 1:43 pm | N/A 2035-03-31 | ACTUATE THERAPEUTICS INC. | ACTU | Mazar Andrew Paul Chief Operating Officer | 161,392 | $0 | 161,392 (Direct) | View |
Ownership | 2024-08-12 9:47 pm | N/A N/A | ACTUATE THERAPEUTICS INC. | ACTU | Mazar Andrew Paul Chief Operating Officer | 0 | $0 | 164,624 (Direct) | View |
| 2022-03-31 Exercise | 2022-04-01 5:28 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 1,606 | $0 | 4,388,857 (Direct) | View |
| 2022-03-31 Tax Withholding | 2022-04-01 5:28 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 471 | $2.55 | 4,388,857 (Direct) | View |
| 2022-02-02 Option Award | 2022-02-04 7:38 pm | N/A 2032-02-01 | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 156,125 | $0 | 179,272 (Direct) | View |
| 2022-01-01 Exercise | 2022-01-04 2:49 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 1,937 | $0 | 4,302,804 (Direct) | View |
| 2022-01-01 Tax Withholding | 2022-01-04 2:49 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 671 | $3.21 | 4,302,804 (Direct) | View |
| 2021-12-31 Exercise | 2022-01-04 2:40 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 1,606 | $0 | 4,316,937 (Direct) | View |
| 2021-12-31 Tax Withholding | 2022-01-04 2:40 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 556 | $3.21 | 4,316,937 (Direct) | View |
| 2021-09-30 Exercise | 2021-10-01 7:31 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 1,606 | $0 | 4,317,493 (Direct) | View |
| 2021-09-30 Tax Withholding | 2021-10-01 7:31 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 471 | $4.87 | 4,317,493 (Direct) | View |
| 2021-06-30 Tax Withholding | 2021-07-02 5:11 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 942 | $5.89 | 4,317,964 (Direct) | View |
| 2021-06-30 Exercise | 2021-07-02 5:11 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 3,212 | $0 | 4,317,964 (Direct) | View |
| 2021-01-26 Option Award | 2021-01-28 6:49 pm | N/A 2031-01-25 | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 61,774 | $0 | 67,585 (Direct) | View |
| 2021-01-01 Tax Withholding | 2021-01-05 5:38 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 671 | $6.12 | 4,424,020 (Direct) | View |
| 2021-01-01 Exercise | 2021-01-05 5:38 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 1,937 | $0 | 4,424,020 (Direct) | View |